Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Supernus PharmaceuticalsLTS:0LB2 +1.55%87 Cash Ratio is 1.03 as of Mar. 2026, which is 9% below its 10-year median of 1.13. GuruFocus rates LTS:0LB2 with a GF Score™ of 87/100 and a GF Value™ of $41.79 (Modestly Overvalued). Among 975 Drug Manufacturers companies, Supernus Pharmaceuticals ranks better than 62.26% on this metric.
Supernus Pharmaceuticals has a Cash Ratio of 1.03. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Supernus Pharmaceuticals's Cash Ratio or its related term are showing as below:
LTS:0LB2'
s Cash Ratio Range Over the Past 10 Years
Min: 0.31 Med: 1.13 Max: 4.11
Current: 1.03
During the past 13 years, Supernus Pharmaceuticals's highest Cash Ratio was 4.11. The lowest was 0.31. And the median was 1.13.
LTS:0LB2's Cash Ratio is ranked better than 62.26% of 975
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs LTS:0LB2: 1.03
Supernus Pharmaceuticals (LTS:0LB2) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Supernus Pharmaceuticals Cash Ratio Related Terms
Supernus Pharmaceuticals Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (LTS:0LB2) has a Cash Ratio of 1.03 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Supernus Pharmaceuticals and its competitors. This is near median its historical median of 1.13. Over the past decade, Supernus Pharmaceuticals' Cash Ratio has ranged from 0.31 to 4.11. According to the industry distribution chart, Supernus Pharmaceuticals ranks #368 out of 975 companies in the Drug Manufacturers industry, placing it in the top 37.7%.
Is Supernus Pharmaceuticals' Cash Ratio too high?
Supernus Pharmaceuticals' current Cash Ratio of 1.03 is near median its 10-year median of 1.13. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 4.11. The Drug Manufacturers industry median Cash Ratio is 0.61. Supernus Pharmaceuticals' value of 1.03 is 68.9% above this industry median. Based on the distribution chart, Supernus Pharmaceuticals ranks #368 out of 975 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Supernus Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Cash Ratio compare to RGC and BCRX?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #368 out of 975 companies for Cash Ratio. This puts Supernus Pharmaceuticals in the upper half of its industry. The industry median Cash Ratio is 0.61. Supernus Pharmaceuticals' value of 1.03 is 68.9% above this benchmark. Historically, Supernus Pharmaceuticals' own Cash Ratio has ranged from 0.31 to 4.11 over the past decade. While the company's 10-year median is 1.13 vs. the industry median of 0.61, Supernus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supernus Pharmaceuticals's current Cash Ratio of 1.03 is 68.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Supernus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current Cash Ratio is 1.03, which is near median its own 10-year median of 1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $41.79, compared to a current price of $48.56 — trading 16.2% above its estimated fair value. The current Cash Ratio is 1.03, which is near median its 10-year median of 1.13 and 68.9% above the Drug Manufacturers industry median of 0.61. Supernus Pharmaceuticals' overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Cash Ratio is 1.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $48.56 is trading 16.2% above its estimated GF Value™ of $41.79.
GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LTS:0LB2:
Cash Ratio: 1.03 (near median its 10-year median of 1.13)
GF Value™: $41.79 vs. price of $48.56 (16.2% above fair value)
Industry Position: 68.9% above the Drug Manufacturers median (#368 of 975)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
87GF Score
Get the complete analysis for LTS:0LB2
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
